JRCT ID: jRCT2022210040
Registered date:01/10/2021
Pilot study of dMD-002 in patients with neurovascular bundles injury during radical prostatectomy -
Basic Information
Recruitment status | Not Recruiting |
---|---|
Health condition(s) or Problem(s) studied | Prostate cancer |
Date of first enrollment | 01/10/2021 |
Target sample size | 12 |
Countries of recruitment | |
Study type | Interventional |
Intervention(s) | The cut dMD-002 is implanted to cover the nerve injury, tear, or defect, and is fixed by suturing to the surrounding tissue in two or more places. |
Outcome(s)
Primary Outcome | Efficacy Change in EHS Change in IIEF EF Change in EPIC sxual function(Q17 to 23) Safety Advere event defect |
---|---|
Secondary Outcome |
Key inclusion & exclusion criteria
Age minimum | >= 20age old |
---|---|
Age maximum | < 75age old |
Gender | Male |
Include criteria | (1) Patients diagnosed with prostate cancer (2) Patients scheduled for radical prostatectomy (non-nerve sparing or unilateral nerve-sparing) by robot-assisted laparoscopic surgery etc. |
Exclude criteria | (1) Patients required radiation therapy, endocrine therapy or antineoplastic therapy before or after radical prostatectomy (2) Patients taking PDE5 inhibitors (3) Patients using negative pressure erection apparatus |
Related Information
Primary Sponsor | Nakamura Masaki |
---|---|
Secondary Sponsor | |
Source(s) of Monetary Support | Sponsored research |
Secondary ID(s) |
Contact
Public contact | |
Name | Public relations |
Address | 7, Yotsuya 1-chome, Shinjuku-ku, Tokyo Tokyo Japan 160-8515 |
Telephone | +81-3-3225-6303 |
webmaster@mochida.co.jp | |
Affiliation | Mochida Pharmaceutical Co., Ltd. |
Scientific contact | |
Name | Masaki Nakamura |
Address | 7, Yotsuya 1-chome, Shinjuku-ku, Tokyo 160-8515, Japan Tokyo Japan 160-8515 |
Telephone | +81-3-3225-6306 |
dmd001.mdbd@mochida.co.jp | |
Affiliation | Mochida Pharmaceutical Co., Ltd. |